|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF292 |
Gene summary for ZNF292 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF292 | Gene ID | 23036 |
| Gene name | zinc finger protein 292 | |
| Gene Alias | MRD63 | |
| Cytomap | 6q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O60281 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23036 | ZNF292 | P128T-E | Human | Esophagus | ESCC | 5.44e-33 | 1.02e+00 | 0.1241 |
| 23036 | ZNF292 | P130T-E | Human | Esophagus | ESCC | 5.43e-57 | 1.06e+00 | 0.1676 |
| 23036 | ZNF292 | NAFLD1 | Human | Liver | NAFLD | 5.22e-09 | 9.56e-01 | -0.04 |
| 23036 | ZNF292 | S43 | Human | Liver | Cirrhotic | 8.65e-06 | -1.09e-01 | -0.0187 |
| 23036 | ZNF292 | HCC1_Meng | Human | Liver | HCC | 3.54e-46 | -2.15e-02 | 0.0246 |
| 23036 | ZNF292 | HCC2_Meng | Human | Liver | HCC | 7.35e-32 | 2.66e-01 | 0.0107 |
| 23036 | ZNF292 | cirrhotic1 | Human | Liver | Cirrhotic | 9.24e-03 | 7.16e-02 | 0.0202 |
| 23036 | ZNF292 | cirrhotic2 | Human | Liver | Cirrhotic | 8.08e-04 | 4.02e-02 | 0.0201 |
| 23036 | ZNF292 | HCC1 | Human | Liver | HCC | 1.08e-05 | 4.49e+00 | 0.5336 |
| 23036 | ZNF292 | HCC2 | Human | Liver | HCC | 2.71e-18 | 5.63e+00 | 0.5341 |
| 23036 | ZNF292 | Pt13.b | Human | Liver | HCC | 5.45e-05 | 7.80e-02 | 0.0251 |
| 23036 | ZNF292 | S014 | Human | Liver | HCC | 1.84e-08 | 6.30e-01 | 0.2254 |
| 23036 | ZNF292 | S015 | Human | Liver | HCC | 4.05e-07 | 6.03e-01 | 0.2375 |
| 23036 | ZNF292 | S016 | Human | Liver | HCC | 1.02e-13 | 6.96e-01 | 0.2243 |
| 23036 | ZNF292 | S027 | Human | Liver | HCC | 4.93e-09 | 8.54e-01 | 0.2446 |
| 23036 | ZNF292 | S028 | Human | Liver | HCC | 5.39e-15 | 9.72e-01 | 0.2503 |
| 23036 | ZNF292 | S029 | Human | Liver | HCC | 2.04e-13 | 8.66e-01 | 0.2581 |
| 23036 | ZNF292 | RNA-P17T-P17T-2 | Human | Lung | IAC | 7.49e-04 | 6.72e-01 | 0.3371 |
| 23036 | ZNF292 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.74e-04 | 7.75e-01 | 0.343 |
| 23036 | ZNF292 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.44e-04 | 6.71e-01 | 0.3385 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF292 | SNV | Missense_Mutation | novel | c.6965N>A | p.Arg2322Lys | p.R2322K | O60281 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.8085N>T | p.Lys2695Asn | p.K2695N | O60281 | protein_coding | tolerated(0.08) | benign(0.05) | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.4842N>A | p.Asn1614Lys | p.N1614K | O60281 | protein_coding | deleterious_low_confidence(0.01) | benign(0.076) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| ZNF292 | SNV | Missense_Mutation | c.1202A>T | p.Asp401Val | p.D401V | O60281 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ZNF292 | SNV | Missense_Mutation | c.3904G>C | p.Glu1302Gln | p.E1302Q | O60281 | protein_coding | tolerated(0.25) | benign(0.261) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF292 | SNV | Missense_Mutation | c.5485G>A | p.Glu1829Lys | p.E1829K | O60281 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF292 | SNV | Missense_Mutation | novel | c.471G>T | p.Glu157Asp | p.E157D | O60281 | protein_coding | deleterious(0.04) | benign(0.189) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.1493C>A | p.Ser498Tyr | p.S498Y | O60281 | protein_coding | deleterious(0.02) | possibly_damaging(0.804) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.5817G>T | p.Lys1939Asn | p.K1939N | O60281 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | rs756555025 | c.2552N>T | p.Ser851Phe | p.S851F | O60281 | protein_coding | tolerated(0.06) | benign(0.046) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |